首頁 › 黑色素瘤 › 哥倫比亞特區 › Washington
Washington, DC 的 黑色素瘤 臨床試驗
17 項針對 黑色素瘤 的研究正在 Washington（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
招募中觀察性研究歡迎健康志工
- National Cancer Institute (NCI), Bethesda · 距離 7 英里
- National Institutes of Health Clinical Center, Bethesda · 距離 7 英里
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
招募中2 期
- National Institutes of Health Clinical Center, Bethesda · 距離 7 英里
Evaluation for NCI Surgery Branch Clinical Research Protocols
招募中觀察性研究
- National Institutes of Health Clinical Center, Bethesda · 距離 7 英里
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 距離 7 英里
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
招募中3 期
- National Cancer Institute, Bethesda · 距離 7 英里
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
招募中1 期
- National Institutes of Health Clinical Center, Bethesda · 距離 7 英里
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
招募中1/2 期
- Sibley Memorial Hospital, Washington D.C.
Project: Every Child for Younger Patients With Cancer
招募中觀察性研究
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · 距離 7 英里
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Children's National Medical Center, Washington D.C.
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
招募中2 期
- National Institutes of Health Clinical Center, Bethesda · 距離 7 英里
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
招募中1/2 期
- National Institutes of Health Clinical Center, Bethesda · 距離 7 英里
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- National Institutes of Health, Bethesda · 距離 7 英里
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
招募中2 期
- USA11-0, Bethesda · 距離 7 英里
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
招募中觀察性研究歡迎健康志工
- Cancer Support Community Research & Training Institute, Washington D.C.
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
招募中2/3 期
- Georgetown University Medical Center, Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Silver Spring · 距離 7 英里
- Massive Bio SYNERGY-AI site, Bethesda · 距離 7 英里
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
招募中
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
其他城市的 黑色素瘤 試驗
- Houston, TX59 項研究
- New York City, NY38 項研究
- Los Angeles, CA34 項研究
- Nashville, TN33 項研究
- Pittsburgh, PA31 項研究
- Boston, MA26 項研究
- Philadelphia, PA23 項研究
- San Francisco, CA22 項研究
- St. Louis, MO21 項研究
- Durham, NC21 項研究
- Atlanta, GA21 項研究
- Columbus, OH21 項研究
Washington 的其他研究
- 癌症（所有類型）58 項研究
- 非小細胞肺癌55 項研究
- 乳癌46 項研究
- 轉移性癌症43 項研究
- 肺癌41 項研究
- 前列腺癌38 項研究
- 肥胖症33 項研究
- 大腸直腸癌29 項研究
- 心血管疾病28 項研究
- 膀胱癌26 項研究
- 急性髓系白血病24 項研究
- 卵巢癌23 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。